Hyperprolactinemia with Aripiprazole: a Case Report and Review of the Literature
Ayşe Nur İnci Kenar, Gülfizar Sözeri Varma
Abstract
Open-access reader
Ayşe Nur İnci Kenar, Gülfizar Sözeri Varma
Abstract
Open-access reader
Hyperprolactinemia is an important but often a neglected side effect of antipsychotic treatment. Aripiprazole is one of the new atypical antipsychotics that has partial agonist effects on dopamine D2 receptors and has a low possibility of hyperprolactinemia. In the present case report, we discuss a female patient who was diagnosed as suffering from depression with psychotic symptoms. Her prolactin levels were elevated while on treatment with aripiprazole. Clinicians should consider that aripiprazole may result in moderate elevation of prolactin levels although it is reported that it has a lower risk of elevation of prolactin levels.
OpenAlex reports 6 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Hyperprolactinemia is an important but often a neglected side effect of antipsychotic treatment. Aripiprazole is one of the new atypical antipsychotics that has partial agonist effects on dopamine D2 receptors and has a low possibility of hyperprolactinemia. In the present case report, we discuss a female patient who was diagnosed as suffering from depression with psychotic symptoms. Her prolactin levels were elevated while on treatment with aripiprazole. Clinicians should consider that aripiprazole may result in moderate elevation of prolactin levels although it is reported that it has a lower risk of elevation of prolactin levels.
Key concepts: Aripiprazole, Partial agonist, Prolactin, Agonist, Depression (economics), Dopamine agonist, Dopamine receptor D2, Medicine